Precision Biologics, Inc. (“Precision”), a clinical-stage immunotherapy and targeted oncology company, announces that the U.S....
Dr. Philip M. Arlen gives Immunotherapy Section Opening Keynote at Festival of Biologics 2022, San...
Dr. Joyson Karakunnel joins the Board of Directors of Precision Biologics, Inc. as its newest...
November 12th: poster number 883 (12:40–2:10 p.m. and 7–8:30 p.m.) Title: An anti-carcinoma monoclonal antibody (mAb)...
Dr. Philip M. Arlen gives scientific presentation at Biomarkers UK: In-Person, Day 1 – November...
The Phase 2 Clinical Trial with a safety lead in, combining Precision Biologics monoclonal antibody...
Dr Massimo Fantini, Director of Research is Presenting the following Talk entitled : “Stability Tests...
Precision Biologics announces that a Phase 2 Clinical Trial, combining NEO-201 with Pembrolizumab, is recruiting...
Dr. Philip M. Arlen gives scientific presentation at the 4th Annual Europe Neoantigen summit, Clinical...
Dr. Philip M. Arlen gives scientific presentation at the Festival of Biologics, World Immunotherapy Congress,...